Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CFO Mark Ragosa sold 17,845 shares of the company's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $43.28, for a total transaction of $772,331.60. Following the completion of the transaction, the chief financial officer owned 12,086 shares in the company, valued at $523,082.08. This represents a 59.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Mark Ragosa also recently made the following trade(s):
- On Thursday, January 8th, Mark Ragosa sold 12,000 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.89, for a total transaction of $502,680.00.
- On Monday, December 8th, Mark Ragosa sold 42,841 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $41.49, for a total value of $1,777,473.09.
Kiniksa Pharmaceuticals International Stock Up 0.6%
KNSA opened at $44.98 on Thursday. The stock's fifty day moving average is $42.06 and its two-hundred day moving average is $38.68. The company has a market capitalization of $3.41 billion, a P/E ratio of 99.96 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a 52 week low of $18.25 and a 52 week high of $45.50.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on KNSA shares. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "strong sell" rating in a report on Tuesday, January 13th. Citigroup increased their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a "buy" rating in a research note on Friday, October 17th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research note on Sunday, November 2nd. Wedbush increased their target price on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an "outperform" rating in a research report on Tuesday, January 13th. Finally, The Goldman Sachs Group lifted their price target on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a "buy" rating in a report on Wednesday, October 29th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of "Moderate Buy" and a consensus price target of $52.33.
View Our Latest Stock Report on Kiniksa Pharmaceuticals International
Institutional Investors Weigh In On Kiniksa Pharmaceuticals International
Several institutional investors have recently bought and sold shares of KNSA. Rubric Capital Management LP increased its position in shares of Kiniksa Pharmaceuticals International by 2.3% during the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company's stock worth $155,320,000 after purchasing an additional 90,194 shares in the last quarter. Vanguard Group Inc. grew its stake in Kiniksa Pharmaceuticals International by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company's stock worth $128,409,000 after buying an additional 49,802 shares during the last quarter. Acadian Asset Management LLC increased its position in Kiniksa Pharmaceuticals International by 22.6% during the 2nd quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company's stock valued at $35,067,000 after buying an additional 233,668 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in Kiniksa Pharmaceuticals International by 45.3% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company's stock valued at $41,481,000 after buying an additional 332,846 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its stake in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company's stock valued at $24,581,000 after buying an additional 653,236 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.
About Kiniksa Pharmaceuticals International
(
Get Free Report)
Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.
The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
